Microsoft’s Strategy In Health Care: Connection, Not Disruption
Through an ever-growing number of partnerships, grants and investments in the health care sector, Microsoft is taking a lead from behind approach to improve and expand interoperability, increase data security and analytics, and provide partners with tools, technology, and a platform for growth.
You may also be interested in...
Two European pharmaceutical companies, UCB and Merck KGaA, are exploring artificial intelligence in different ways, the first for drug discovery and the second on a fundamental level.
A two and half year-old partnership between Adaptive Biotechnologies and Microsoft that began with a focus on Lyme disease has transitioned to mapping immune responses to the SARS-CoV-2 virus. By identifying and matching T cell receptors to antigens associated with the virus – and leveraging the power of machine learning – the companies hope to improve COVID-19 vaccine development, locate potential antibodies for drug development and create better, more sensitive diagnostics.
New five-year deal shows convergence of big pharma and big tech continues – though both sectors are wary of hype surrounding AI and digital health.